Panic Disorder Market Report and Forecast 2024-2032

Panic Disorder Market Report and Forecast 2024-2032


Panic Disorder Market Report and Forecast 2024-2032

Panic Disorder Market Outlook

The panic disorder market size was valued at USD 9.7 billion in 2023, driven by growing recognition of mental health disorders in the major markets. The market size is anticipated to grow at a CAGR of 4.18 % during the forecast period of 2024-2032 to achieve a value of USD 14 billion by 2032.

Panic Disorder: Introduction

Panic Disorder is a mental health condition characterized by sudden, intense episodes of fear or discomfort known as panic attacks. These attacks can include symptoms like heart palpitations, sweating, trembling, and feelings of impending doom. Individuals may worry excessively about future attacks and avoid situations they associate with panic. The exact cause is unknown, but factors like genetics, stress, and changes in brain function may contribute. Treatment typically involves therapy, medication, or a combination of both.

Key Trends in the Panic Disorder Market

There's a growing recognition of mental health disorders, including panic disorder, leading to earlier diagnosis and treatment. Public health campaigns and educational programs are reducing stigma and encouraging individuals to seek help.

The market is seeing innovation in treatment methods, including the development of new pharmacological treatments with fewer side effects. Personalized medicine is becoming more prevalent, tailoring treatments to individual genetic profiles and symptoms.

Digital health solutions, like mobile apps for anxiety management and telepsychiatry services, are on the rise. These technologies offer remote monitoring, therapy, and support, making treatment more accessible and convenient.

There's an increasing interest in holistic approaches, including mindfulness, yoga, and dietary changes, often used alongside conventional treatments. This trend reflects a broader shift towards comprehensive, patient-centered care.

CBT remains a cornerstone in the treatment of panic disorder, with ongoing research and development of new, more effective therapy models. There's a trend towards integrating CBT with other therapies and adapting it for diverse populations and settings.

Panic Disorder Market Segmentation

Market Breakup by Type
  • Agoraphobia
  • Social Anxiety Disorder (SAD)
  • Obsessive-Compulsive Disorder (OCD)
  • Bipolar Disorder
  • Post-Traumatic Stress Disorder (PTSD)
  • Specific Phobias, Generalized Anxiety Disorder (GAD)
  • Major Depressive Disorder (MDD)
  • Others
Market Breakup by Therapy
  • Electroconvulsive Therapy ECT
  • Cognitive-Behavioral Therapy (CBT)
Market Breakup by Drug Class
  • Benzodiazepines (BZD)
  • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Anti-Depressants
  • Tricyclic Antidepressants (TCAs)
  • Pregabalin
  • Buspirone
  • Sertraline
  • Others
Market Breakup by Route of Administration
  • Oral
  • Parenteral
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Panic Disorder Market Overview

In North America, the panic disorder market is influenced by a high prevalence of anxiety disorders and a growing awareness of mental health issues. The region has a well-established healthcare infrastructure with widespread access to mental health services. There's a significant emphasis on therapy and counseling, along with a robust market for psychiatric medications. Public health initiatives and private organizations actively promote mental health education and support, contributing to the market's dynamics.

Europe's market is marked by comprehensive healthcare systems and strong mental health policies. There's a focus on early diagnosis and treatment, with countries like the UK, Germany, and France leading in mental health research and services. The region shows a preference for psychotherapy and holistic treatment approaches, alongside traditional medication. EU regulations and initiatives aimed at reducing the stigma around mental health further shape the market, encouraging individuals to seek treatment.

Japan market is evolving, driven by changing attitudes towards mental health and improving healthcare infrastructure. It is experiencing increased recognition of panic disorder and other mental health conditions. However, cultural attitudes and limited access to mental health services in some areas pose challenges. The region shows potential growth in the pharmaceutical sector and a gradual increase in mental health awareness and services.

Panic Disorder Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Mylan
  • AstraZeneca
  • Abbott
  • Baxter
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Recordati S.p.A.
  • Boehringer Ingelheim International GmbH.
  • Neurocrine Biosciences, Inc
  • Recordati S.p.A.
  • Sanofi
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Panic Disorder Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Panic Disorder Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Panic Disorder Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Panic Disorder Epidemiology Forecast (2017-2032)
5.3.1 Germany Panic Disorder Epidemiology Forecast (2017-2032)
5.3.2 France Panic Disorder Epidemiology Forecast (2017-2032)
5.3.3 Italy Panic Disorder Epidemiology Forecast (2017-2032)
5.3.4 Spain Panic Disorder Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Panic Disorder Epidemiology Forecast (2017-2032)
5.4 Japan Panic Disorder Epidemiology Forecast (2017-2032)
6 Panic Disorder Market Overview – 7MM
6.1 Panic Disorder Market Historical Value (2017-2023)
6.2 Panic Disorder Market Forecast Value (2024-2032)
7 Panic Disorder Market Landscape – 7MM
7.1 Panic Disorder Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Panic Disorder Product Landscape
7.2.1 Analysis by Diseases Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
8 Panic Disorder Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Panic Disorder Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Panic Disorder Market Segmentation – 7MM
11.1 Panic Disorder Market by Type
11.1.1 Market Overview
11.1.2 Agoraphobia
11.1.3 Social Anxiety Disorder (SAD)
11.1.4 Obsessive-Compulsive Disorder (OCD)
11.1.5 Bipolar Disorder
11.1.6 Post-Traumatic Stress Disorder (PTSD)
11.1.7 Specific Phobias, Generalized Anxiety Disorder (GAD)
11.1.8 Major Depressive Disorder (MDD)
11.1.9 Others
11.2 Panic Disorder Market by Therapy
11.2.1 Market Overview
11.2.2 Electroconvulsive Therapy ECT
11.2.3 Cognitive-Behavioral Therapy (CBT)
11.3 Panic Disorder Market by Drug Class
11.3.1 Market Overview
11.3.2 Benzodiazepines (BZD)
11.3.3 Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
11.3.4 Monoamine Oxidase Inhibitors (MAOIs)
11.3.5 Anti-Depressants
11.3.6 Tricyclic Antidepressants (TCAs)
11.3.7 Pregabalin
11.3.8 Buspirone
11.3.9 Sertraline
11.3.10 Others
11.4 Panic Disorder Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.5 Panic Disorder Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
12 United States Panic Disorder Market
12.1 Panic Disorder Market Historical Value (2017-2023)
12.2 Panic Disorder Market Forecast Value (2024-2032)
12.3 Panic Disorder Market by Disease Type
12.4 Panic Disorder Market by Treatment Type
13 EU-4 and United Kingdom Panic Disorder Market
13.1 Panic Disorder Market Historical Value (2017-2023)
13.2 Panic Disorder Market Forecast Value (2024-2032)
13.3 Germany Panic Disorder Market Overview
13.3.1 Panic Disorder Market by Disease Type
13.3.2 Panic Disorder Market by Treatment Type
13.4 France Panic Disorder Market Overview
13.4.1 Panic Disorder Market by Disease Type
13.4.2 Panic Disorder Market by Treatment Type
13.5 Italy Panic Disorder Market Overview
13.5.1 Panic Disorder Market by Disease Type
13.5.2 Panic Disorder Market by Treatment Type
13.6 Spain Panic Disorder Market Overview
13.6.1 Panic Disorder Market by Disease Type
13.6.2 Panic Disorder Market by Treatment Type
13.7 United Kingdom Panic Disorder Market Overview
13.7.1 Panic Disorder Market by Disease Type
13.8 Panic Disorder Market by Treatment Type
14 Japan Panic Disorder Market
14.1 Panic Disorder Market Historical Value (2017-2023)
14.2 Panic Disorder Market Forecast Value (2024-2032)
14.3 Panic Disorder Market by Disease Type
14.4 Panic Disorder Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Teva Pharmaceutical Industries Ltd
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Sun Pharmaceutical Industries Ltd.
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Mylan
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 AstraZeneca
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Abbott
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.5.6 BaxterFinancial Analysis
20.5.7 Product Portfolio
20.5.8 Demographic Reach and Achievements
20.5.9 Mergers and Acquisition
20.5.10 Certifications
20.6 Baxter
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Bristol-Myers Squibb Company
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Eli Lilly and Company
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 F. Hoffmann-La Roche Ltd
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 GlaxoSmithKline plc
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Recordati S.p.A.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Boehringer Ingelheim International GmbH.
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Neurocrine Biosciences, Inc
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Recordati S.p.A.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Sanofi
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Panic Disorders Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings